Loading company
Indaptus Therapeutics, Inc.
INDP · Nasdaq · ·
Next earnings: November 11, 2026
$2.86-13.3%Sep 29 close
- 1M
- +150.9%
- 6M
- +60.7%
- 1Y
- -0.3%
- 5Y
- -98.7%
INDP · Nasdaq · ·
Next earnings: November 11, 2026
$2.86-13.3%Sep 29 close
Indaptus Therapeutics, Inc. is scheduled to report next on November 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$1.8M | -$5.2M | +65.67% |
| Profit per share | -$0.02 | -$0.47 | +95.74% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Indaptus Therapeutics, Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Indaptus Therapeutics is a biotechnology company dedicated to immunotherapy research. The Company’s patented Decoy technology uses attenuated and killed, non-pathogenic Gram-negative bacteria designed to activate multiple components of innate and adaptive immunity while reducing systemic toxicity. The Company is evaluating the Decoy platform and existing therapeutic assets while also assessing complementary research capabilities, strategic investments and potential business combinations. The Company seeks to better understand the relationship among sleep, physical recovery, neurological function and immune status, which could potentially support future immunotherapy evaluation, patient recovery monitoring and biomarker research. The scope and timing of any such activities will depend on scientific validation, strategic fit, market opportunities, available resources, regulatory considerations and other business factors.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Indaptus Therapeutics, Inc.’s Item 2.02 8-K filed August 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.